Evénements Archive - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Evénements Archive - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s

May 2025

2025 ASCO Annual Meeting
February 2025

Lusvertikimab & the Future of IBD: KOL Insights Post-ECCO
February 2025

Smallcap Event, Paris
December 2024

20th Congress of European Crohn’s and Colitis Organization (ECCO)
December 2024

2025 JPM HEALTHCARE CONFERENCE
September 2024

European Society for Medical Oncology (ESMO)
September 2024

Word Conference on Lung Cancer (WCLC)
January 2024

BIO-EUROPE Spring®
January 2024

Symposium on Resolution of Inflammation in Medicine and Surgery, Harvard Medical School
January 2024

KEYSTONE SYMPOSIA on Molecular and Cellular Biology
  • 1
  • 2
  • 3
  • 4
  • 5
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris